Howard L. Kaufman
#145,405
Most Influential Person Now
Researcher
Howard L. Kaufman's AcademicInfluence.com Rankings
Howard L. Kaufmanengineering Degrees
Engineering
#5648
World Rank
#6911
Historical Rank
Electrical Engineering
#1593
World Rank
#1688
Historical Rank
Howard L. Kaufmancomputer-science Degrees
Computer Science
#7253
World Rank
#7640
Historical Rank
Computational Linguistics
#1417
World Rank
#1433
Historical Rank
Machine Learning
#2620
World Rank
#2655
Historical Rank
Artificial Intelligence
#2914
World Rank
#2959
Historical Rank
Download Badge
Engineering Computer Science
Howard L. Kaufman's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Howard L. Kaufman Influential?
(Suggest an Edit or Addition)Howard L. Kaufman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (2015) (1780)
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017) (1274)
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. (2016) (950)
- Oncolytic viruses: a new class of immunotherapy drugs (2015) (734)
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (2011) (645)
- Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. (2009) (574)
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. (2016) (513)
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma (2010) (484)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (2017) (426)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. (2016) (421)
- Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. (2006) (349)
- Integrating oncolytic viruses in combination cancer immunotherapy (2018) (348)
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. (2016) (303)
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial (2018) (302)
- Comparison of RNA-seq and microarray-based models for clinical endpoint prediction (2015) (292)
- Combination immunotherapy: a road map (2017) (287)
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial (2018) (259)
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy (2016) (257)
- Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. (2004) (247)
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial (2016) (238)
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy (2015) (227)
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma (2019) (221)
- Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. (1992) (217)
- Erratum: Oncolytic viruses: a new class of immunotherapy drugs (2016) (214)
- OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. (2010) (212)
- Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule (2000) (208)
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (2010) (191)
- A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer (2006) (185)
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma (2014) (184)
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma (2017) (173)
- Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. (2009) (166)
- OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. (2013) (165)
- Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. (2003) (153)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes (2001) (149)
- Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. (2018) (147)
- Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. (2005) (129)
- Palmitoylation of Caveolin-1 at a Single Site (Cys-156) Controls Its Coupling to the c-Src Tyrosine Kinase (2001) (128)
- Clinical landscape of oncolytic virus research in 2020 (2020) (124)
- The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. (2004) (121)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 (2014) (115)
- Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer (2019) (104)
- Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer (2008) (103)
- Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer (2007) (102)
- Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma (2017) (101)
- Discovery and clinical introduction of first-in-class imipridone ONC201 (2016) (100)
- Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. (1992) (97)
- Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo (2013) (96)
- First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors (2017) (94)
- A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) (1991) (93)
- Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions (2013) (93)
- Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. (2014) (93)
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy (2015) (93)
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial (2016) (91)
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation (2018) (88)
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study (2016) (84)
- Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery (2016) (84)
- Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy (2008) (83)
- Activation of Rho Kinase by TNF-α Is Required for JNK Activation in Human Pulmonary Microvascular Endothelial Cells1 (2008) (82)
- Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. (2006) (80)
- Biomarkers for Immunotherapy: Current Developments and Challenges. (2016) (78)
- Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients1 (2007) (78)
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma (2016) (75)
- Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (2009) (75)
- Quantitative Analysis of Immune Infiltrates in Primary Melanoma (2018) (75)
- First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients (2012) (73)
- Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. (2015) (72)
- Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression (2011) (72)
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma (2019) (70)
- Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. (2015) (66)
- Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. (2007) (66)
- Oncolytic viruses: a new class of immunotherapy drugs (2016) (64)
- Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 (2019) (63)
- The promise of Immuno-oncology: implications for defining the value of cancer treatment (2019) (62)
- Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) (2020) (62)
- Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers (2016) (61)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer (1996) (57)
- Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. (2017) (57)
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (57)
- Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. (2009) (57)
- Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. (2004) (56)
- An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (2018) (55)
- Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA. (2002) (54)
- Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. (2009) (54)
- Poxviruses as vectors for cancer immunotherapy. (2003) (54)
- Immunotherapy for melanoma. (2004) (53)
- Cytokine therapy for cancer. (2007) (53)
- NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade (2015) (53)
- Immune oncology, immune responsiveness and the theory of everything (2018) (51)
- Development of the PANVAC™-VF vaccine for pancreatic cancer (2006) (51)
- Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. (2002) (49)
- Oncolytic virus therapy for cancer. (2013) (49)
- Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment. (1998) (47)
- Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. (2015) (47)
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma (2016) (47)
- High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions (2017) (47)
- Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. (1999) (46)
- Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma (2017) (46)
- The tumour microenvironment and implications for cancer immunotherapy (2006) (45)
- Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment (2018) (45)
- Strategies for cancer therapy using carcinoembryonic antigen vaccines (2000) (44)
- Cancer immunotherapy trials: leading a paradigm shift in drug development (2016) (43)
- Colonic ulceration associated with nonsteroidal anti-inflammatory drugs (1996) (43)
- Intratumoral Approaches for the Treatment of Melanoma (2017) (43)
- Statistical methods on detecting differentially expressed genes for RNA-seq data (2011) (43)
- Pox viral vaccine approaches. (2005) (43)
- Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer (2018) (42)
- 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. (2006) (41)
- Oncolytic Virus Immunotherapy for Melanoma (2015) (41)
- Poxvirus vaccines for cancer and HIV therapy (2004) (40)
- TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development (2010) (39)
- A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. (2016) (38)
- Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood (2013) (37)
- Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials (2017) (36)
- Immunotherapy for Merkel cell carcinoma: a turning point in patient care (2018) (35)
- MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients (2011) (35)
- Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (1993) (34)
- Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. (2000) (33)
- Gene therapy with poxvirus vectors. (2005) (33)
- Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses (2014) (33)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
- Vaccines for melanoma and renal cell carcinoma. (2012) (32)
- Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897 (2005) (32)
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma (2016) (32)
- Herpes simplex virus oncolytic vaccine therapy in melanoma (2010) (31)
- Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. (2002) (31)
- Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. (2015) (31)
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
- Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression (2016) (29)
- Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. (2004) (29)
- CEA-based vaccines (2002) (29)
- A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. (2001) (29)
- Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM (2016) (29)
- Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress12 (2014) (28)
- Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial (2017) (28)
- Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry (2019) (28)
- A new mouse model for evaluating the immunotherapy of human colorectal cancer. (2001) (27)
- Management of metastatic malignant melanoma of the bladder. (2003) (27)
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry (2017) (27)
- The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma (2015) (27)
- Innovative treatments for pancreatic cancer. (2001) (27)
- Targeting Costimulatory Pathways for Tumor Immunotherapy (2007) (26)
- CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. (2014) (26)
- Surgical Management of Melanoma. (2016) (26)
- Talimogene laherparepvec (T-VEC) as cancer immunotherapy. (2015) (26)
- Immunotherapy for Non-melanoma Skin Cancer (2021) (25)
- Management of Metastatic Melanoma in 2018 (2018) (25)
- Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) (2014) (25)
- Two roads for oncolytic immunotherapy development (2019) (24)
- IFN-λ cancer immunotherapy: new kid on the block. (2016) (24)
- Immunotherapy for pancreatic cancer: current concepts. (2002) (24)
- Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update (2017) (24)
- Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. (2018) (24)
- Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. (2006) (23)
- OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC (2017) (22)
- Intrarectal Vaccination with Recombinant Vaccinia Virus Expressing Carcinoembronic Antigen Induces Mucosal and Systemic Immunity and Prevents Progression of Colorectal Cancer1 (2008) (22)
- Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development (2018) (22)
- Leiomyoma of the breast (1996) (22)
- Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma (2014) (22)
- A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma. (2000) (21)
- An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions (2020) (20)
- Next generation approaches for tumor vaccination. (2017) (20)
- Biomarkers for Immunotherapy: Current Developments and Challenges. (2016) (20)
- First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. (2017) (20)
- Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma (2015) (20)
- Unleashing the therapeutic potential of oncolytic viruses. (2018) (19)
- Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. (2016) (19)
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis (2018) (19)
- Prostate-specific antigen vaccines for prostate cancer (2002) (18)
- Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). (2015) (18)
- Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma (2021) (18)
- Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases (2018) (18)
- A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. (2008) (17)
- Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles (2004) (17)
- First-inHuman Clinical Trial of Oral ONC 201 in Patients with Refractory Solid Tumors (2019) (17)
- Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011) (16)
- Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. (2009) (16)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. (2016) (15)
- Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma (2012) (15)
- Extended survival in second-line pancreatic cancer after therapeutic vaccination (2005) (15)
- Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. (2003) (15)
- The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2) (2014) (15)
- Surgical treatment of stage IV melanoma. (2004) (15)
- Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma (2016) (14)
- Oncolytic viruses: focusing on the tumor microenvironment (2015) (14)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- The role of poxviruses in tumor immunotherapy. (2003) (13)
- TroVax(®) vaccine therapy for renal cell carcinoma. (2012) (13)
- Local delivery of poxvirus vaccines for melanoma. (2003) (13)
- The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting (2017) (13)
- Avelumab and other recent advances in Merkel cell carcinoma. (2017) (13)
- The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma (2005) (13)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. (2016) (13)
- TG-4010 Transgene. (2004) (13)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors. (2005) (12)
- Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) (2018) (12)
- Current issues in cancer vaccine development. (1999) (12)
- Optimizing Prostate Cancer Treatment by Combining Local Radiation Therapy with Systemic Vaccination (2005) (12)
- Chemokines in tumor immunotherapy. (2006) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). (2014) (11)
- Molecular targeting in oncology (2008) (11)
- Combination interleukin-2 and interleukin-12 induces severe gastrointestinal toxicity and epithelial cell apoptosis in mice. (2002) (11)
- Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells (2014) (11)
- Viral vaccines for cancer immunotherapy. (2006) (10)
- Imaging the immune response to monitor tumor immunotherapy (2009) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Characteristics of patients diagnosed with both melanoma and renal cell cancer (2013) (10)
- Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer. (2004) (10)
- Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee (2020) (10)
- Immunotherapy for Nonmelanoma skin cancer: Facts and Hopes. (2022) (10)
- Advancing oncolytic virus therapy by understanding the biology (2021) (9)
- Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma. (2014) (9)
- Clinical Infection Control in Gene Therapy: A Multidisciplinary Conference (2000) (9)
- Vaccines for Colorectal Cancer and Renal Cell Carcinoma (2011) (9)
- Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes But Does Not Affect Prognosis (2007) (9)
- General principles of tumor immunotherapy : basic and clinical applications of tumor immunology (2007) (9)
- Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model (2014) (9)
- Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences (2018) (9)
- Current Approaches to Novel Therapeutics in Pancreatic Cancer (2003) (9)
- CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. (2013) (9)
- Adjuvant therapy for malignant melanoma (2004) (9)
- Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. (2014) (9)
- Precision immunology: the promise of immunotherapy for the treatment of cancer. (2015) (9)
- The next generation of vaccines for the treatment of cancer. (1999) (9)
- Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. (2017) (8)
- Administration of vaccinia virus to mice may cause contact or bedding sentinel mice to test positive for orthopoxvirus antibodies: case report and follow-up investigation. (2003) (8)
- HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice. (2014) (8)
- Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. (2014) (8)
- Phase II trial of Modified Vaccinia Ankara ( MVA ) virus expressing 5 T 4 and high dose Interleukin-2 ( IL-2 ) in patients with metastatic renal cell carcinoma (2008) (8)
- Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. (2005) (8)
- A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. (2011) (8)
- High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma (2020) (8)
- Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma (2016) (7)
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. (2015) (7)
- Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma (2013) (7)
- Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2 (2021) (7)
- First-inman application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian , breast and prostate cancer patients (2012) (6)
- Oncolytic Immunotherapy. (2019) (6)
- Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
- Real-world assessment of response to anti-PD-1 therapy in advanced cutaneous squamous cell carcinoma. (2021) (6)
- Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. (2020) (6)
- Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study. (2014) (6)
- Gene therapy for antitumor vaccination. (2009) (6)
- 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts (2020) (6)
- Melanoma as a model for precision medicine in oncology. (2014) (6)
- Society for Melanoma Research 2015 Congress (2015) (6)
- Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class (2022) (6)
- Innovations and strategies for the development of anticancer vaccines (2000) (6)
- Therapy with oncolytic viruses: progress and challenges (2023) (5)
- Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules (2005) (5)
- 1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA. (2014) (5)
- An update on TroVax® for the treatment of progressive castration-resistant prostate cancer (2011) (5)
- Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy. (2017) (5)
- Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma (2019) (5)
- Rational Combination Immunotherapy: Understand the Biology (2017) (5)
- Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy (2018) (5)
- High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. (2014) (5)
- Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry. (2016) (5)
- AIDS: Testing Democracy - Irrational Responses to the Public Health Crisis and the Need for Privacy in Serologic Testing, 19 J. Marshall L. Rev. 835 (1986) (1986) (5)
- Can Biomarkers Guide Oncolytic Virus Immunotherapy? (2021) (5)
- A phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. (2006) (5)
- Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (5)
- Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma (2008) (4)
- Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes (2014) (4)
- Cancer vaccines and immunotherapy: Vaccines for colon cancer (2000) (4)
- Introduction on Cancer Immunology and Immunotherapy (2020) (4)
- General Principles of Tumor Immunotherapy (2007) (4)
- Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. (2013) (4)
- 1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA. (2014) (4)
- 1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. (2014) (4)
- Combination Cytokine Therapy (2007) (4)
- Modulating the Tumor Microenvironment (2012) (4)
- An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL). (2013) (4)
- A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma (2022) (4)
- Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit (2020) (3)
- Clinical Applications of P53-Directed Gene Therapy (2002) (3)
- Patient experiences with avelumab vs chemotherapy for treating merkel cell carcinoma: Results from protocol-specified qualitative research. (2017) (3)
- Chemokines and Cancer (2002) (3)
- Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy. (2017) (3)
- Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study (2021) (3)
- Radiation Therapy and Talimogene Laherparepvec (TVEC) Synergize in the Treatment of Melanoma (2017) (3)
- A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. (2015) (3)
- Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry. (2015) (3)
- 1227PAvelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC) (2017) (3)
- Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. (2020) (3)
- Combination Immunotherapy for Melanoma. (2015) (3)
- Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2). (2017) (3)
- Avelumab: is it time to get excited? (2018) (3)
- Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma (2021) (3)
- Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21. (2016) (3)
- A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma. (2016) (3)
- Metastasectomy following incomplete response to high‐dose interleukin‐2 (2018) (3)
- High Dose Interleukin-2 Therapy (2007) (3)
- Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies (2016) (3)
- Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2. (2016) (3)
- Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. (2011) (3)
- An association between corticosteroid use and melanoma recurrence: a case report and review of the literature (2012) (3)
- Management of Metastatic Melanoma to the Breast with High‐Dose Interleukin‐2 and Surgical Resection (2005) (3)
- Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma (2016) (3)
- Diagnostic Yield of Staging Brain MRI is Low in Merkel Cell Carcinoma: A Single-Institution Cohort Study. (2021) (3)
- Allograft Rejection in Humanized SCID Soluble Ig-Like Transcript 3 Inhibits Tumor (2007) (2)
- OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma. (2012) (2)
- Mosenson Mutant HSP 70 Reverses Autoimmune Depigmentation in Vitiligo (2013) (2)
- 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM (2015) (2)
- Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma (2015) (2)
- Clinical utility of cell-free DNA liquid biopsies in Merkel cell carcinoma. (2021) (2)
- Vaccines against Cancer (2014) (2)
- An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. (2019) (2)
- Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2). (2016) (2)
- A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies. (2021) (2)
- Patient Perspectives on Merkel Cell Carcinoma (MCC) and Its Treatment with A Novel Agent (AVELUMAB): Findings From In-Depth Qualitative Patient Interviews (2016) (2)
- A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). (2018) (2)
- Avelumab Immunotherapy (2019) (2)
- Combined Radiation and Oncolytic Viral Therapy Augments Cytotoxic and Immunogenic Antitumor Effects Against Melanoma (2018) (2)
- 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors (2020) (2)
- First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients (2012) (2)
- High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes. (2014) (2)
- First-in-human trial of ONC201 in patients with refractory solid tumors. (2016) (2)
- Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment (2014) (2)
- Intratumorally anchored cytokine therapy (2022) (2)
- Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC). (2016) (1)
- Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. (2023) (1)
- Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule (2016) (1)
- High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates (2013) (1)
- Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma (2004) (1)
- Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin-2 (2006) (1)
- Abstract 1470: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1 (2019) (1)
- Cancer Immunotherapy with Interleukin-2—The PROCLAIMSM Registry (2016) (1)
- Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood (2013) (1)
- Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2 (2008) (1)
- Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease (2013) (1)
- Clinical Management ofMultipleMelanoma BrainMetastases A Systematic Review (2015) (1)
- Safety profile of therapeutic pox virus-based vaccines for cancer (2004) (1)
- Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade (2019) (1)
- Synthetic biology: at the crossroads of genetic engineering and human therapeutics—a Keystone Symposia report (2021) (1)
- Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). (2017) (1)
- Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 (2014) (1)
- Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. (2017) (1)
- Abstract PR05: Exceptional Response to PD-1 antibody treatment in a POLE-mutant endometrial cancer (2015) (1)
- Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 (2015) (1)
- Cytokines in the Treatment of Cancer (2013) (1)
- Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy (2017) (1)
- A novel non-HLA-restricted cellular immune assay for monitoring patient (pt) response to targeted immunotherapeutics. (2006) (1)
- P238: Mucosal vaccination prevents spontaneous colorectal carcinoma and induces long-term immunity in mice (2007) (1)
- P239: CCR5 polymorphism as a predictor of clinical resonse to high-dose IL-2 therapy in melanoma and renal cell carcinoma (2007) (1)
- Adjuvant therapy for malignant (2004) (1)
- Safety profile of therapeutic pox virus-based vaccines for cancer. (2004) (1)
- High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry. (2018) (1)
- Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time? (2023) (1)
- NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with CTLA-4 blockade and IL-2 (TUM2P.1039) (2015) (1)
- The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma. (2021) (1)
- Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. (2012) (1)
- Abstract 365: Intratumoral delivery of aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response (2022) (0)
- Oncolytic Viruses (2021) (0)
- Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 (2021) (0)
- the way in the development of a rational approach to the use of precision medicine for cancer treatment. (2014) (0)
- Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy. (2010) (0)
- Real-world assessment of ipilimumab plus nivolumab in anti-PD-L1/PD-1- refractory Merkel Cell Carcinoma (2022) (0)
- Mutant HSP70i prevents effector T cell responses in autoimmune vitiligo (P4352) (2013) (0)
- Minimal Impact on Patients’ Health Utilities Associated with Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment with Avelumab (2017) (0)
- 20 Combination Cytokine Therapy (0)
- Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex (2013) (0)
- 3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses (2015) (0)
- Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells (2014) (0)
- A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma (2023) (0)
- Tu1692 HIV Infection Accelerates Gastrointestinal Tumor Outgrowth in Humanized NSG-HuPBL Mice (2014) (0)
- Skin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues (2023) (0)
- Comprar General Principles of Tumor Immunotherapy · Basic and Clinical Applications of Tumor Immunology | Kaufman, Howard L. | 9781402060861 | Springer (2008) (0)
- Avelumab Produces Durable Responses in Metastatic Merkel Cell Carcinoma (2016) (0)
- Overall survival of patients enrolled in trial compared with historical control (2011) (0)
- Surgical factors affecting regionally metastatic cutaneous squamous cell carcinoma to the parotid gland (2023) (0)
- Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2017) (0)
- A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma. (2015) (0)
- DNA Vaccines for Cancer Immunotherapy (2006) (0)
- The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) (2013) (0)
- Vaccines as Targeted Cancer Therapy (2008) (0)
- Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series. (2021) (0)
- The Test: Is It Accurate? - Is It Legal?, 14 Hum. Rts. 30 (1987) (1987) (0)
- A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS). (2015) (0)
- CCR5 gene polymorphism in patients with cutaneous melanoma: impact on survival following immunotherapy (2006) (0)
- Durable response rates with talimogene laherparepvec or granulocyte-macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB-IVM1a melanoma in the OPTiM trial (2016) (0)
- 664 Applying advanced data analysis to immunotherapy drug discovery for Uveal Melanoma (2020) (0)
- Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2 (2016) (0)
- Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) (2015) (0)
- 1268 Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: a multi-institutional cohort study (2022) (0)
- 477 Deep learning to drive COVID-19 rapid drug repurposing (2020) (0)
- an Oncolytic Vaccinia Virus Expressing 4-1 BB Ligand Host Lymphodepletion Enhances the Therapeutic Activity of (2009) (0)
- The lymphoid chemokine CCL19 (ELC) promotes T cell proliferation in vitro and mediates T cell migration when expressed in a recombinant vaccinia virus: A strategy for local tumor vaccine delivery (2004) (0)
- Embracing a Standard of Care for Merkel Cell Carcinoma With Immunotherapy (2016) (0)
- Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard? (2023) (0)
- Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. (2017) (0)
- Complete surgical resection of residual melanoma metastasis and survival in stage IV patients following high-dose IL-2 therapy (2008) (0)
- Viral-Based Therapies in Melanoma (2018) (0)
- TNF-{alpha}-induced activation of RhoA/Rho kinase pathway in human pulmonary microvascular endothelial cells (2007) (0)
- Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. (2018) (0)
- 81PHealth-related quality of life (HRQoL) in patients (Pts) with Merkel cell carcinoma (MCC) receiving avelumab (2017) (0)
- Clinical Protocol A Phase I Trial of Intralesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma (2001) (0)
- Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma. (2004) (0)
- Abstract 2091: Quantitative compositional and spatial analysis of tumor microenvironment (TME) in primary melanoma (2018) (0)
- Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial (2014) (0)
- Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival (2013) (0)
- Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry. (2017) (0)
- Integrating oncolytic viruses in combination cancer immunotherapy (2018) (0)
- Abstract 4640: Randomized, phase 1 crossover study assessing the bioequivalence of tablet and capsule formulations of dovitinib (TKI258) (2014) (0)
- TNF‐α‐induced activation of RhoA/Rho kinase pathway in human pulmonary microvascular endothelial cells (0)
- 721 Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity (2021) (0)
- Combination Immunotherapy forMelanoma (2015) (0)
- Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on “Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies” (2021) (0)
- de cas The contralateral sentinel node (2005) (0)
- Single-Incision Laparoscopic Surgery for Intra-Abdominal Metastatic Melanoma (2011) (0)
- Finding gold in tumour immunotherapy. (2017) (0)
- A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. (2022) (0)
- A Phase 1 Trial of RP1: A New Oncolytic Virus Alone and in Combination with Nivolumab (2020) (0)
- 1076 Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response (2022) (0)
- Combination immunotherapy utilizing influenza infection and PD-1 blockade reduces lung melanoma tumor growth (TUM2P.1011) (2015) (0)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
- Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry. (2015) (0)
- DEVELOPMENT OF A RECOMBINANT VACCINIA-CARCINOEMBRYONIC ANTIGEN (CEA) VACCINE FOR IMMUNOTHERAPY OF HUMAN CARCINOMA (1993) (0)
- Association Between Tumour Lesion Size and Health-Related Quality of Life Outcomes in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab (2017) (0)
- What Surgeons Need to Know About Gene Therapy for Cancer. (2022) (0)
- Tumor Microenvironment Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1 BB Ligand (2009) (0)
- The impact of age on a mitoxantrone-based tumor vaccine (2013) (0)
- Characteristics of patients diagnosed with both melanoma and renal cell cancer (2013) (0)
- The contralateral sentinel node. (2005) (0)
- Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy (2015) (0)
- The Use of Oncolytic Herpesvirus for the Treatment of Cancer (2014) (0)
- Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy (2007) (0)
- Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy (2018) (0)
- Comparison of RNA-seq and microarray-based models for clinical endpoint prediction (2015) (0)
- High Dose Systemic Interleukin-2 for Metastatic Melanoma in Patients with Treated Brain Metastases (2004) (0)
- Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) (2020) (0)
- Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel cell carcinoma. (2017) (0)
- Summer 1986 AIDS : Testing Democracy-Irrational Responses to the Public Health Crisis and the Need for Privacy in Serologic Testing (2016) (0)
- Modified Oncolytic Herpesviruses for Gene Therapy of Cancer (2014) (0)
- 3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704) (2015) (0)
- Caloric restriction responses can maintain immune responses during aging (47.14) (2012) (0)
- Oncolytic Virotherapy Oncolytic virus therapy for cancer (2013) (0)
- Erratum: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model (Journal of Immunotherapy (1999) 22 (489-496)) (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Howard L. Kaufman?
Howard L. Kaufman is affiliated with the following schools:
